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Hypertension (HTN) is a devastating disease with a higher incidence in African Americans than European Americans,
inspiring searches for genetic variants that contribute to this difference. We report the results of a large-scale
admixture scan for genes contributing HTN risk, in which we screened 1,670 African Americans with HTN and 387
control individuals for regions of the genome with elevated proportion of African or European ancestry. No loci were
identified that were significantly associated with HTN. We also searched for evidence of an admixture signal at 40
candidate genes and eight previously reported linkage peaks, but none appears to contribute substantially to the
differential HTN risk between African and European Americans. Finally, we observed nominal association at one of the
loci detected in the admixture scan of Zhu et al. 2005 (p ¼ 0.016 at 6q24.3 correcting for four hypotheses tested),
although we caution that the significance is marginal and the estimated odds ratio of 1.19 per African allele is less than
what would be expected from the original report; thus, further work is needed to follow up this locus.
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Introduction
Essential hypertension (HTN) is a widely prevalent con-
dition with devastating clinical consequences including
stroke, myocardial infarction, heart failure, and chronic
kidney disease. Familial aggregation studies have established
HTN as a complex trait, with both environmental and genetic
determinants, and heritability for blood pressure has been
estimated at about 30% [1]. Although HTN is prevalent
worldwide (with particular abundance in developed coun-
tries), disease prevalence varies with ethnicity. In the United
States, African Americans are disproportionately susceptible
to HTN compared with other ethnic groups; they had an
adjusted 1.6-fold higher prevalence of HTN than European
Americans (and 2.5-fold higher than Mexican Americans) in
the National Health and Nutritional Examination Survey
(NHANES) in 2003–2004 [2]. The higher risk of HTN in
African Americans has been hypothesized to be due (at least
in part) to genetic risk variants that exist at a higher
frequency in the ancestral African population than the
ancestral European population [3]. Moreover, mean bio-
chemical characteristics, such as plasma renin activity,
urinary kallikrein and dopamine levels, differ between
African Americans and European Americans with HTN,
suggesting potentially different mechanisms of blood pres-
sure elevation [4].
Admixture mapping is a technique that searches for
genetic variants that differ strikingly in frequency between
continental populations, and also contribute to disease. The
idea of admixture mapping is to screen through the genome
in a population of recently mixed ancestry, such as African
Americans, identifying genome segments where in people
with disease, there is a substantial deviation in the proportion
of one of the parental ancestries from the genome-wide
average. We speciﬁcally searched for regions with elevated
African ancestry, based on the known higher rate of HTN in
people of African ancestry.
Although the idea of admixture mapping is not new, it has
only recently been implemented in practice with the
introduction of panels of ancestry-informative markers [5,6]
and statistical data analysis methods for detection of disease
genes [7–10]. To date, four genome-wide admixture mapping
scans have been published: one for HTN [11], one for
multiple sclerosis [12], one for prostate cancer [13] and one
for inﬂammatory biomarkers [14]. In addition to offering a
novel method for identifying genetic determinants of HTN,
admixture scans of HTN in African American may offer
insights into the differences in salt-handling and blood
pressure regulation between Africans/African Americans
and European Americans; these differences are epidemiolog-
ically well-established and could be due to either genetic or
non-genetic causes (see for example [15]).
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For our analyses, we studied a data set of 1,165 individuals
with HTN and 387 control individuals from the Multiethnic
Cohort (MEC) [16] and a second data set of 505 individuals
with HTN from the Genomics Collaborative (GCI) Study. The
two studies differ in location of participants, method of data
collection, and HTN phenotype deﬁnition (see Materials and
Methods for study characteristics). Demographic character-
istics for the two cohorts, as well as information on some
important HTN covariates, are summarized in Table 1.
The 1,670 individuals with HTN and 387 control individ-
uals were genotyped using one of two panels of markers
selected for high differences in frequency between West
Africans and European Americans. A total of 911 individuals
from the MEC were genotyped in the phase one panel,
originally described in reference [12]. The remaining 641
MEC samples and 505 GCI samples were genotyped in a
somewhat improved second-generation phase two panel,
originally described in references [14,17].
African Genetic Ancestry Is Not Significantly Higher in
African Americans with HTN than in Control Individuals
The ANCESTRYMAP software [7] allows us to make precise
estimates of individual African ancestry, which can be tested
for correlation to HTN status. We ﬁnd a trend towards
increased African ancestry in hypertensive individuals (0.760)
relative to control individuals (0.749) in the MEC; however, the
result does not achieve statistical signiﬁcance. The addition of
the African/European ancestry term to a logistic regression
model predicting HTN status that includes age, body mass
index (BMI), and type II diabetes mellitus status (T2DM) also
fails to signiﬁcantly improve the ﬁt of the model (unpublished
data). Previous studies have also found a nonsigniﬁcant trend
of HTN with increasing African ancestry [11,18],
Admixture Mapping Detects No Significant or Suggestive
Associations to HTN in Each Study Treated Separately
We carried out the genome-wide admixture scan by
genotyping our 1,554 markers in the 1,670 individuals with
HTN and 387 control participants. The resulting data were
analyzed using two methods (Table 2): (a) an affected-only
statistic, which calculates likelihood of association based on
an estimate of the ancestry at a particular location relative to
the overall average of the individual’s genome (obviating the
need for a separate control group), and (b) a case-control
statistic, which measures the average ancestry deviation at a
particular location in individuals with HTN and compares
this with control participants [7]. While the affected-only
statistic theoretically has more power to detect risk loci, the
case-control statistic ensures that any deviation in African
ancestry from the genome-wide average is present only in
people with disease (for example, a locus unrelated to the
disease could have been under selection some time in the
recent history of the African American population, causing a
rise in African ancestry relative to the average in the genome,
irrespective of disease status).
We found no evidence for association to HTN. The
genome-wide score, obtained by averaging the evidence of
association at equally spaced points across the genome is 0.1
in the MEC and 0.6 for GCI, which does not meet our
published thresholds of 1 for suggestiveness or 2 for
signiﬁcance [19]. The maximum local LOD score is 1.9 in
the MEC and 3.3 in the GCI study (Table 2, Figure 1), again
falling short of our published threshold of suggestiveness
(LOD ¼ 4) or signiﬁcance (LOD ¼ 5) [19].
We Observed No Association with HTN after Combining
Both Studies
Admixture mapping allows the merging of individuals with
disease and control participants from multiple cohorts. This
Table 1. Demographic Characteristics for the Participants
Demographic Characteristic MEC Participants with HTN MEC Control Participants GCI Participants
n 1,165 387 505
Percent male 100 100 45
Age (mean y 6 SD) 70.2 6 6.7 67.8 6 7.4 57.8 6 13.5
BMI (mean kg/m
2 6 SD) 28.1 6 4.3 26.0 6 3.8 31.5 6 7.0
Percent with T2DM 21.4 4.7 9
Percent taking medication 100 0 100
Percent with family history of HTN 23
SBP (mmHg) 143 6 19
DBP (mmHg) 88 6 11
Age at HTN diagnosis (mean y 6 SD) 47.8 6 12.6
doi:10.1371/journal.pgen.0030196.t001
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Author Summary
High blood pressure is more frequent and severe among African
Americans than European Americans. To explore whether there are
genetic underpinnings to this pattern, we screened the genomes of
1,670 African Americans, searching for loci at which people with
hypertension (HTN) have more than the average proportion of African
ancestry (eighty percent). We do not detect any region of clearly
significant association. In a previous, smaller admixture scan for HTN
genes, Zhu and colleagues (2005) reported two regions of association,
which we would have expected to replicate if they were as strong as
they initially appeared. While we detect marginal evidence of
association at one, the signal is very weak, and much weaker than
would have been expected from the previous report, so further work
is necessary to understand this region. Our results are consistent with
there being no common variants with a strong effect accounting for
differences in HTN prevalence between African and European
Americans. This increases the weight of evidence that non-genetic
causes explain most of the difference in rates across populations.can increase the power to detect risk alleles with small effects,
although merging data from cohorts collected in different
ways can also weaken signals by combining heterogeneous
phenotypes. We merged data from the MEC and GCI, yielding
a total of 1,670 individuals with HTN and 387 control
participants. The global genome-wide LOD score for the
combined data was  0.03, indicating that the null hypothesis
of no disease locus is slightly more favored than the
hypothesis of a disease locus somewhere in the genome.
The highest local LOD score applying the affected-only
statistic was 2.09 on the X chromosome (Figure 1). The site on
chromosome 4 with the highest LOD scores in the GCI scan
showed a weakened LOD ¼ 1.39 in the combined scan.
We Found Little Evidence for Ancestry-Related Differences
in HTN Risk at 40 Commonly Studied HTN Candidate
Genes
One concern with whole genome scanning for disease
variants is the risk of false negatives, with true disease variants
buried underneath the noise of many loci, which necessitated
a large correction for multiple hypothesis testing. One
technique that has been proposed to deal with this problem
is to pay special attention to candidate loci based on prior
knowledge from linkage studies, association studies, and
biological studies [20]. There have already been a handful of
studies that mapped genes for extreme forms of HTN or
hypotension [21], dozens of whole genome linkage scans for
HTN, and thousands of candidate gene association studies
[22,23]. In principle, taking these previous studies into
account should help to prioritize signals in whole genome
scans. To take advantage of this insight, we identiﬁed a small
set of particularly plausible loci, to which we paid special
attention even if the loci did not meet stringent thresholds of
statistical signiﬁcance correcting for scanning the whole
genome.
We ﬁrst carried out a focused analysis of 40 candidate genes
previously identiﬁed in association studies (Table 3), and
which we selected in three ways. First we searched PubMed
(http://www.ncbi.nlm.nih.gov/sites/entrez?db¼PubMed), the
Genetic Association Database [24], and the HUGE Database
(www.cdc.gov/genomics/hugenet) for genetic association stud-
ies involving HTN or blood pressure. We focused on genes
with variants that demonstrated convincing association with
HTN or blood pressure in two independent populations (see
Materials and Methods for details of selection process). The
genes we selected were primarily implicated in the renin-
angiotensin-aldosterone axis, the adrenergic system, salt
homeostasis, and T2DM. Second, we selected eight candidate
loci based on their containing genes known to be causal in
familial forms of HTN or hypotension; some of these overlap
with those from the ﬁrst category [21]. Third, we selected ﬁve
candidate loci highlighted in a recent study by Young et al.
[3], which focused on genetic variants implicated in salt
handling and heat dissipation that show substantial world-
wide frequency differences and marked differences between
Sub-Saharan Africa and Northern Europe.
For each of the 40 genes, we calculated odds ratios (and
credible intervals) for their admixture association to HTN
risk in the combined GCI–MEC scan (Materials and Methods).
Only three of these loci have a 90% credible interval that
excludes no risk due to ancestry: AGTR1, CYP4A11, and
WNK1. The WNK1 and AGTR1 genes both show increased
HTN risk with inheritance of the African allele, which is the
direction that might be expected given that African Amer-
icans have a higher rate of HTN (we estimate an increased
risk for HTN of 1.11 and 1.14 for inheritance of one copy of
the African allele at these loci, respectively). These signals of
Table 2. Top Loci Determined by HTN Participants-Only and Participant-Control Statistic for MEC, GCI, and Combined MECþGCI
Admixture Scans
Population Locus Participants-Only Statistic Participant-Control Statistic
Top loci determined by
participant-only statistic
MEC 1p32.3 1.939 1.209
6q25.1 1.357  0.208
Xp22.11 1.204  1.228
Xp11.3 1.920  2.602
Xq21.32 1.189  1.237
GCI 2q24.2 1.888  2.757
4q35.2 3.288  2.129
13q32.1 1.485 2.453
16q22.3 1.917 3.385
Xq27.2 1.147  0.823
MECþGCI 1p32.1 1.618 0.371
1p22.3 1.542 1.270
4q35.2 1.390  0.869
Xp22.2 2.091  1.157
Xp11.3 1.821  2.494
Top loci determined by
participant-control statistic
MECþGCI 4p15.1  1.128  3.197
11q24.3  1.168 2.748
13q14.12  0.829 2.403
16q23.3 0.319 2.932
Xp11.3 1.821  2.494
doi:10.1371/journal.pgen.0030196.t002
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tested. Moreover, because of the substantial extent of
admixture linkage disequilibrium, even if these signals are
real they may simply represent the effect of alleles of nearby
genes rather than the proposed candidate genes. Admixture
scanning of additional samples and other follow-up will be
necessary to conﬁrm these are genuine associations.
No Overlap of Admixture Signals with Previously Reported
Linkage Peaks
We also tested whether the admixture signals we found
correlated with previously reported linkage peaks. Table 4
includes credible intervals for the top loci found in a recent
meta-analyses of whole genome linkage scans for blood
pressure traits [25–27]. In our admixture scan, none of these
loci showed a signiﬁcant association of ancestry with HTN
risk.
One of the Four Strongest Loci in a Previously Published
Admixture Scan for HTN Shows Evidence for an Increase
in HTN Risk with African Ancestry
Our scan can also be compared with the previous
admixture mapping study for HTN, which identiﬁed two
main candidate loci for association and two secondary loci
[11]. We calculated odds ratios and credible intervals for all
four of these peaks. Figure 2 demonstrates LOD scores for the
6q24.3, 2p25.1, 21q21, and 3q13.31 loci across a range of risk
models. Overall, we ﬁnd weak evidence for association with
HTN for the 6q24.3 locus, with estimated odds ratios for HTN
of 1.19 (95% credible interval 1.06–1.34, p ¼ 0.004 by
likelihood ratio test; p ¼ 0.016 with Bonferroni correction
for four hypotheses). For the 6q24.1 locus, there is an
increased risk of HTN with inheritance of the African
ancestral allele. This is the same direction that was also seen
in the original report, although the quantitative effect is less
than would have been necessary to generate the signal in
reference [11].
Ruling Out .95% of the Genome as Contributing Strong
Risk Due to Ancestry
We constructed an exclusion map to rule out most loci in
the genome as contributing substantially increased risk due
to African or European ancestry. To obtain the exclusion
map we estimated a conﬁdence interval, for each position in
the genome, for the factor by which the risk due to African
(or European) ancestry differs from the risk due to European
(or African) ancestry at that locus (Materials and Methods).
For the 1,670 hypertensive individuals, 95.9% of the genome
could be excluded as having risks . 1.3-fold due to African
ancestry, and 98.7% could be excluded as having risks . 1.3-
fold due to European ancestry at a signiﬁcance of p , 0.05
(Table 5). The percentages of the genome excluded at various
levels of risk are shown in Table 5. As our participants derive
from two separate populations with different HTN deﬁni-
tions, we expect some loss of power from combining samples.
We therefore also constructed an exclusion map with
participants from the larger MEC cohort only. The percent-
age of the genome excluded using the MEC participants is
shown in parentheses in Table 5, and reveals that, at a
signiﬁcance level of p , 0.05, 95.4% and 98.4% of the genome
could be excluded as having risks . 1.3-fold due to African
ancestry and European ancestry, respectively.
Inclusion of HTN Covariates Fails to Identify HTN Loci
Numerous covariates are known to affect blood pressure,
including age, smoking, BMI, T2DM, and alcohol use. We
considered the possible contribution of these covariates to
the admixture association to HTN in two ways. Since T2DM is
known to have an effect on blood pressure, we performed an
admixture scan using only the 1,378 individuals with HTN but
without T2DM from MEC and GCI. This revealed no
signiﬁcant or suggestive loci, with a genome-wide score of
 0.1 and a peak LOD score of 1.8. We also attempted to
address the presence of multiple covariates by constructing a
logistic regression model for MEC HTN status including age,
BMI, and T2DM, all of which are known HTN covariates, and
all of which showed a signiﬁcant association with HTN status
in the MEC cohort. Using this model, we sought to identify
surprising occurrences of HTN, which could not be
accounted for by these three covariates. To do so, we
determined the Pearson residual [28] for each individual,
ranked participants in order of decreasing residual, and
selected the top 25 percent of participants (highest residuals)
for analysis. These should represent relatively lean, young,
non-diabetic hypertensive individuals. Using the same re-
gression model, we determined the Pearson residual for the
Figure 1. Genome-Wide Admixture Scans of a Total of 1,670 Participants with HTN and 387 Control Participants from GCIþMEC Do Not Reveal a Locus
for Hypertension Risk
The GCIþMEC combined scan yielded top LOD scores of 2.1 and 1.8 for peaks at Xp22 and Xp11 respectively, with a genome-wide score of  0.03.
doi:10.1371/journal.pgen.0030196.g001
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who passed the cutoff deﬁned in the MEC cohort. We then
performed an admixture scan on the 482 individuals from
MECþGCI in the top 25 percent of HTN severity and
compared them with 387 MEC control individuals. The
genome-wide score is 0.0 (highest local LOD ¼ 1.8), which
does not reach statistical signiﬁcance.
Discussion
We have completed the largest and highest density HTN
admixture scan to date and failed to identify any loci that are
signiﬁcantly, or even suggestively, associated with HTN after
correcting for multiple hypothesis testing. Our large sample
size also allows us to exclude . 95% of the genome as
harboring risk loci of . 1.3 due to African or European
ancestry. Although we cannot rule out weak ancestry effects,
the negative results suggest that there may be no common
variants with a strong effect accounting for differences in
HTN prevalence between African and European Americans.
These results thus increase the weight of evidence that non-
genetic causes (diet and environment) contribute to the
different epidemiology across populations.
An intriguing aspect of this study is the analysis of four loci
from a previously reported admixture scan of HTN [11]. We
observed nominal replication of the admixture association at
one of these loci (p ¼ 0.016 correcting for four hypotheses
tested), and the direction of the association (increased HTN
with increased African ancestry) is the same as previously
reported. We caution that these results could represent
statistical ﬂuctuations, as numerous other loci in our scan
scored more strongly. Another concern is that the estimate
for the increased risk for HTN (1.19) arising from the
inheritance of one African allele at this locus is sufﬁciently
small that it would have been very surprising to observe
genome-wide signiﬁcant peaks in a scan with the sample size
and map density studied by Zhu et al. [11]. Further follow-up
studies will be necessary to properly test these loci for
association. A possible way to reconcile the results from the
two studies is that the samples in the Zhu et al. [11] study had
a somewhat different phenotype than the ones we studied.
Their deﬁnition of HTN, with multiple affected family
members, may have been more genetically heritable, and
thus their phenotype may have been more likely to yield
association signals.
We also speciﬁcally evaluated risk at 40 biologically
plausible HTN candidate gene loci as well as eight previously
identiﬁed linkage peaks. For a complex disease, such as HTN,
in which effects are expected to be weak, combining the
wealth of prior genetic and biochemical data with whole
genome scans may be essential for uncovering genes.
Although our data highlight a small number of candidate
loci, including the angiotensin Type I receptor and CYP4A11,
independent studies will be needed for corroboration. We
also examined ﬁve candidate genes that were highlighted by
Young et al. [3], who proposed that HTN may arise from the
interaction of salt-availability in humans populations with
heat-adapted alleles that vary widely in frequency across
populations. None of the ﬁve genes produced an admixture
Table 4. Odds Ratios (with 95% and 90% Credible Intervals) for
HTN Risk Associated with the Inheritance of One African
Ancestral Allele at Eight Plausible HTN Loci Identified from Meta-
Analyses of HTN Linkage Scans
Location Marker Peak Risk
Model
95 Percent
Credible Interval
90 Percent
Credible Interval
2p13 GATA8F03 0.93 0.84–1.03 0.85–1.01
2p22.3 GATA86E02 0.96 0.85–1.07 0.87–1.05
3p14.1 UT7805 1.02 0.91–1.17 0.92–1.14
8q24.2 AFM073YB7 1.02 0.91–1.14 0.92–1.12
9q31.1 GGAA22E01 0.96 0.86–1.07 0.87–1.05
14q32.2 GATA136B01 1.09 0.95–1.26 0.97–1.23
16q12.2 GATA22F09 0.96 0.85–1.08 0.87–1.06
17p11.2 GATA185H04 0.98 0.87–1.10 0.89–1.08
doi:10.1371/journal.pgen.0030196.t004
Table 3. Odds Ratios (with 95% and 90% Credible Intervals) for
HTN Risk Associated with the Inheritance of One African
Ancestral Allele at 40 Plausible HTN Candidate Gene Loci
Odds
Ratio
95 Percent
Credible Interval
90 Percent
Credible Interval
ACE 0.96 0.86–1.09 0.88–1.07
ADD1 1.06 0.90–1.29 0.93–1.25
ADIPOQ 1.06 0.94–1.19 0.96–1.17
ADRB1 1.02 0.92–1.14 0.93–1.12
ADRB2 1.04 0.93–1.18 0.95–1.15
ADRB3 1.02 0.92–1.14 0.93–1.12
AGT 0.98 0.88–1.12 0.90–1.10
AGTR1 1.14 1.00–1.26 1.02–1.24
CORIN 0.94 0.85–1.05 0.86–1.04
CYBA 1.02 0.89–1.15 0.91–1.13
CYP11B2* 1.04 0.90–1.20 0.92–1.18
CYP3A5 0.96 0.87–1.08 0.89–1.06
CYP4A11 0.86 0.79–0.97 0.80–0.96
DRD1 1.09 0.97–1.23 0.99–1.21
ECE1 0.98 0.89–1.12 0.91–1.10
EDN1 0.91 0.83–1.03 0.84–1.01
EDNRA 1.06 0.95–1.21 0.97–1.19
GNAS 1.02 0.92–1.14 0.93–1.12
GNB3 1.06 0.96–1.18 0.97–1.16
GRK4 1.06 0.90–1.29 0.93–1.25
HSD11B2* 0.94 0.84–1.05 0.85–1.03
IL6 1.02 0.91–1.18 0.93–1.15
MMP3 1.04 0.92–1.16 0.94–1.14
MTHFR 1.02 0.90–1.13 0.92–1.11
NOS3 0.94 0.84–1.05 0.85–1.03
NR3C2* 1.06 0.95–1.21 0.97–1.19
PPARG 0.94 0.84–1.06 0.86–1.04
PPARGC1A 1.02 0.93–1.16 0.94–1.14
REN 0.98 0.89–1.11 0.90–1.09
RETN 0.94 0.83–1.07 0.84–1.04
RGS2 0.94 0.85–1.07 0.86–1.05
SCNN1A 1.09 0.96–1.20 0.98–1.18
SCNN1B* 1.04 0.92–1.18 0.94–1.16
SCNN1G* 1.04 0.92–1.18 0.94–1.16
SGK1 1.09 0.95–1.21 0.97–1.18
SLC12A3* 0.98 0.86–1.09 0.88–1.07
SLC4A5 0.96 0.87–1.05 0.88–1.04
TNF 0.98 0.87–1.10 0.89–1.08
WNK1* 1.11 0.98–1.28 1.00–1.25
WNK4* 1.02 0.90–1.12 0.92–1.10
Genes implicated in Mendelian HTN disorders are denoted by an asterisk.
doi:10.1371/journal.pgen.0030196.t003
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substantial amount of differential HTN risk across these
populations.
A potential pitfall for our analysis is that we combined
samples from two different studies, each with a different
deﬁnition of HTN. The GCI study is based on physician-
diagnosis, while the MEC, with its questionnaire-based data
collection, obtains most information from patient self-report.
To increase comparability across the two studies, we
restricted our analysis of the MEC samples to individuals
who reported using HTN-speciﬁc medications, guaranteeing
that both the GCI and MEC samples were physician-treated
individuals with HTN. We also performed additional analyses
with non-diabetics only (since the percentage of participants
with diabetes differed signiﬁcantly in the two studies). We
recognize that the difference in the phenotypes may reduce
power for some analyses, as genetic determinants of HTN
may not have the same effect in the two populations. In
general, in our admixture mapping studies—not only for
HTN, but also for prostate cancer [13] and multiple sclerosis
[12]—we have taken an inclusive approach, analyzing as many
individuals as possible that ﬁt a loose deﬁnition of the
phenotype, and following up marginal peaks by exploratory
analysis across different subgroups. This was successful in
identifying a locus for prostate cancer [13]; however, since it
can also reduce power in some contexts, here we also present
analyses of more homogeneous subgroups.
We conclude by noting that other factors may have
contributed to our inability to identify HTN genetic variants
by admixture mapping. It is possible that the phenotype
deﬁnition we focused on was not sufﬁciently strong. Past
successes at ﬁnding genetic risk factors for HTN have focused
on families with extreme, familial forms of HTN, and here we
aimed to ﬁnd common variants affecting more commonly
observed HTN in the community and the clinic [21]. For
HTN, which is a classic complex trait, there are also a number
of covariates that we did not consider, and that may have
contributed to reduced power for detection of genetic
determinants. In future admixture mapping and whole
genome scans for HTN genes in African Americans, it will
be particularly important to study samples that have been
assessed not only for presence or absence of HTN, but also
for differences in covariates that are known to differ across
populations such as plasma renin activity, urinary kallikrein,
and dopamine levels [4]. This may also offer insights into the
differences in blood pressure and salt handling known to
exist between African and European Americans [15].
Materials and Methods
Participants and control populations. The samples in this study (n¼
2,057) were all self-declared African Americans, and came from the
California component of the MEC (n ¼ 1,552) and from the GCI
CARDIO study (n ¼ 505). MEC is a National Cancer Institute funded
prospective cohort of African Americans, Japanese Americans,
Latinos, Native Hawaiians, and European Americans in California
(mainly Los Angeles) and Hawaii. African Americans in this cohort
were chosen by selecting census tracts in Los Angeles with a
minimum percentage of individuals self-identiﬁed as African
Americans in the 1990 census. Potential cohort members were
identiﬁed through Department of Motor Vehicles drivers’ license ﬁles
and, for African-Americans, Health Care Financing Administration
data ﬁles. Between 1993 and 1996, participants entered the cohort by
completing a 26-page, self-administered (baseline) questionnaire that
asked about diet, demographic factors, and history of prior medical
conditions (e.g., HTN). In 2001, a short follow-up questionnaire was
sent to update information on speciﬁc dietary habits as well as to
obtain information about new diagnoses of medical conditions since
recruitment. In the MEC, hypertensive individuals were deﬁned as
those who indicated on the baseline questionnaire that they had a
history of HTN, and had taken or were taking antihypertensive
medications, and who reported themselves as hypertensive on the
follow-up questionnaire. Normotensive control participants were
deﬁned as those who answered no to all of the above questions [16].
The GCI collection consisted of individuals referred by primary care
physicians or specialists. For patients to be regarded as hypertensive,
they required at least two documented blood pressures . 140/90
prior to the initiation of anti-hypertensive medication. If blood
pressures prior to initiation of medication were not available, then
the patients required two documented blood pressures . 140/90
while under treatment.
Selection of SNPs for the admixture panel. The phase one panel
(911 samples in our study) consisted of 1,824 SNPs, mostly over-
lapping the set described in reference [12]. The core of this panel
Figure 2. An Analysis of LOD Scores at Varying Risk Models Reveals Weak Evidence for Association of Previously Published Loci with HTN
Using the distribution of LOD score shown below, we estimated a HTN odds ratio of 1.19 (95% credible interval 1.06–1.34) for inheritance of the African
allele at the 6p24.1 (GATA184A08) locus, and odds ratios of 1.06 (0.94–1.21), 1.04 (0.95–1.17), and 1.02 (0.92–1.15) for the 2p25.1 (d2s1400), 21q21.1
(d21s1432), and 3q13.31 (d3s2460) loci, respectively.
doi:10.1371/journal.pgen.0030196.g002
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genotyped using the Illumina GoldenGate platform [29]; we then
supplemented this panel with an additional 288 SNPs genotyped on
the Sequenom MassArray and iPLEX platforms [30] to ﬁll in gaps in
the map and increase density at regions of high interest. The phase
two panel (1,146 samples in our study) consisted of 1,566 SNPs, largely
overlapping the panel described in reference [14]. This panel was
constructed by supplementing the database of ancestry informative
markers reported on in Smith et al. [5], with . 1,500 new markers
selected from Hinds et al. [31] as likely to be highly informative about
ancestry and to ﬁll in gaps in the phase one panel. The ﬁnal phase two
panel of SNPs was chosen as the most informative 1,536 SNPs from
the extended database (genotyped on the Illumina GoldenGate
platform), supplemented by 30 SNPs genotyped using the Sequenom
MassArray and iPLEX platforms [30] to increase density in regions of
high interest.
Frequency estimates from the ancestral populations. To obtain
frequency estimates for each of the SNPs in Africans and Europeans,
we used previously published data [5,13]. West African ancestral
frequencies were estimated using samples from Ghana (n ¼ 33),
Cameroon (n¼20), and Nigeria (n¼122). European frequencies were
obtained using samples from Baltimore (n ¼ 38), Chicago (n ¼ 39),
Italy (n ¼ 42), Poland (n ¼ 47) and Utah (n ¼ 93). These samples
provided a Bayesian prior distribution for the allele frequencies in
the parental populations as described in reference [7].
Whole-genome ampliﬁcation of DNA. All the MEC samples were
subjected to whole-genome ampliﬁcation (Molecular Staging) to
produce sufﬁcient DNA sufﬁcient for genotyping [32].
Elimination of poorly performing samples. DNA samples were
excluded if they showed (a) less than 85% genotyping success rate, or
(b) a striking excess or deﬁciency of heterozygote genotypes
compared with that expected from the individual’s estimated
proportion of European ancestry. The high heterozygosity ﬁlter is
aimed at removing individuals who have one European parent, and
who are not correctly modeled by the ANCESTRYMAP software so
that analysis of these samples might weaken statistical power [7]. The
low heterozygosity ﬁlter is aimed at removing individuals with low
quality DNA and high genotyping error rate.
SNP genotyping and quality control. We used a series of criteria for
eliminating SNPs from the analyses. We started with two panels of
SNPs, designated phase one consisting of 1,824 SNPs and phase two
consisting of 1,566 SNPs. A total of 760 SNPs were common to both
panels, leaving 2,630 unique SNPs. Individuals were genotyped in
either the phase one or phase two panel, but not both. We eliminated
SNPs from the analysis by including only those with . 85%
genotyping success rate in African American HTN participants, and
that had reliable genotype clustering patterns as judged by an
experienced research technician (GJM). This left 2,007 SNPs. We next
imposed a requirement for Hardy-Weinberg equilibrium (p . 0.01) in
both the ancestral West African or European American populations.
Finally, we required that the frequency in African American control
participants was appropriately intermediate between ancestral West
Africans and European Americans [7]. This left 1,966 SNPs. We also
eliminated SNPs that demonstrated linkage disequilibrium in the
parental populations, as these are liable to produce false positive
signals of association [19]. After these ﬁlters, we were left with 1,554
markers useable for analysis.
Risk model used in the Markov Chain Monte Carlo data analysis.
The ANCESTRYMAP software described in [7] was used for all
analyses. The program combines information from multiple, densely
spaced markers that are each partially informative about African
versus European ancestry, to produce robust, multipoint estimates.
The LOD score for association is deﬁned as the log ratio of the
likelihood of the data under a disease model, divided by the
likelihood of the data under no disease model. We evaluated LOD
scores at equally spaced points across the genome. At each point, we
used a multiplicative model of risk, with risk of disease integrated
over the inheritance of 0, 1, and 2 copies of an African ancestral
allele. By the convention used in the manuscript, a risk . 1.0 for
inheritance of one African ancestry allele at a given locus describes a
model where African ancestry increases disease risk relative to
European ancestry. The ANCESTRYMAP software uses Bayesian
statistics and thus requires speciﬁcation of a prior distribution on
risk models before carrying out the analysis. We ran a range of risk
models for the MEC, GCI, and MECþGCI samples, and averaged the
LOD score at equally spaced points in the genome (one point every
centimorgan). The prior distribution we used was a range of ten risk
models from 1.6-fold increased risk due to inheritance of one African
ancestral allele to 1.6-fold increased risk due to inheritance of one
European allele.
Selection of candidate HTN genes. We used three overlapping
sources to identify candidate genes: PubMed (http://www.ncbi.nlm.
nih.gov/sites/entrez?db¼PubMed), the Genetic Association Database
[24], and the Human Genetic Epidemiology (HUGE) Database
(www.cdc.gov/genomics/hugenet). We searched PubMed for all refer-
ences mentioning association of genetic variants with HTN or blood
pressure (details of search terms are available upon request). We
performed similar searches using the Genetic Association Database
and the HUGE database. We identiﬁed over two hundred genes for
which variants had been tested for association with HTN. From these,
we selected genes that had positive associations for at least one
variant with blood pressure or HTN in two or more populations. We
restricted ourselves to association studies with at least 100 partic-
ipants with HTN and 100 control participants or 200 total individuals
for quantitative trait evaluation. For each candidate gene, we
identiﬁed the genetic position using Build 35 of the public genome
reference sequence (http://genome.ucsc.edu) and selected the closest
marker to estimate the ancestry-associated HTN risk at that locus.
Exclusion map. To obtain credible intervals for increased risk due
to African ancestry at candidate loci in the genome, we carried out
repeated runs of ANCESTRYMAP, each testing for a different disease
model. The analysis was repeated for 65 disease models, consecutively
running the analysis software for disease risk models of 0.40, 0.42,
0.44, 0.46 ..., 1.66, 1.68 and 1.70-fold increased risk due to one
African allele, and searching for the maximum likelihood risk model.
The 90% and 95% credible intervals for increased risk due to African
ancestry were obtained by a likelihood ratio test: as the range of
models for which the log base ten of the likelihood of the disease
model was within 0.588 and 0.883 of the maximum (we used
Table 5. Proportion of Genome Excluded as Contributing to Differential Risk for HTN Comparing African and European Americans for
Combined GCIþMEC and MEC-Alone Samples
Factor by Which AFRICAN
Ancestry Increases Risk at
This Locus Compared with
European Ancestry
Percent of Genome Excluded as
Having This Risk or More at
p , 0.05: GCIþMEC (MEC)
Factor by Which EUROPEAN Ancestry
Increases Risk at This Locus Compared
with African Ancestry
Percent of Genome Excluded
as Having This Risk or More at
p , 0.05: GCIþMEC (MEC)
1.0 5.0 (5.0) 1.0 5.0 (5.0)
1.1 30.6 (11.4) 1.1 42.6 (58.4)
1.2 77.7 (84.4) 1.2 87.1 (87.1)
1.3 95.9 (95.4) 1.3 98.7 (98.4)
1.4 98.2 (97.8) 1.4 100.0 (100.0)
1.5 98.9 (99.2) 1.5 100.0 (100.0)
The percentage of the genome where the null hypothesis (relative risk due to ancestry ¼ 1) is excluded is about 5% for all scenarios, as expected using a p , 0.05 significance cutoff.
Percentages for the separate MEC cohort analysis are shown in parentheses.
doi:10.1371/journal.pgen.0030196.t005
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Hypertension Admixture Scaninterpolation to extract the disease risk model, accurate to two
decimal places, that met this criterion).
HTN logistic regression model. A logistic regression model was
developed to predict HTN status using the 1,165 MEC HTN
participants and 387 MEC HTN control participants, with age, BMI,
and T2DM status as independent variables. Full covariate informa-
tion was available for 1,132 MEC participants with HTN and all 387
MEC control participants. Using coefﬁcients determined from the
model, the Pearson residual [28] was calculated for each individual.
Individuals were ranked by residual, and the top 25% of individuals
were selected for the analysis. Using the same coefﬁcients, a
regression residual was also calculated for the 505 GCI participants,
and the 199 individuals with residuals above the same cutoff were
selected for a combined admixture scan with the 283 MEC
participants and 387 MEC control participants. All analyses were
performed using Stata 8.0 (StataCorp).
Online resources. See http://genepath.med.harvard.edu/;reich for
our ANCESTRYMAP software.
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